Medicare Hospital, Srinagar, has successfully implanted the first Cobalt CRTD device in the Upper North Region of India in a patient with dilated cardiomyopathy. This patient had an ejection fraction of 20%, LBBB, QRS width of 190 msec and a history of loss of consciousness. He was discharged the next day and is doing well.
The procedure was performed by the renowned interventional cardiologist of jammu and kashmir Dr Syed Maqbool.
Dr. Syed Maqbool has an experience of nearly 500 CRTP/CRTD implants.

Dilated cardiomyopathy (DCM) is the most common cause of heart failure. It is a common cardiac disease in which the heart muscle becomes weak and the pumping of the heart (EF) decreases, leading to heart failure. There are numerous underlying causes of this condition. A few common among them are idiopathic, ischemic heart disease, and viral infections. Common symptoms of this disease are shortness of breath, fatigue, swelling of body, and sometimes loss of consciousness, leading to markedly impaired quality of life, recurrent hospitalization for heart failure, and sudden cardiac death.
Hence, the disease has very high morbidity and mortality if not treated properly and in time.
Various treatment modalities for this disease, in addition to the treatment of underlying causes if an, are medical therapy, CRTP/CRTD implantation, conduction system pacing, and last of all cardiac transplantation.
Few patients improve with medical therapy, but many require cardiac resynchronization therapy in the form of CRTP, CRTD, or conduction system pacing. It is pertinent to mention here that all DCM patients do not benefit from CRT. It is only those patients who have LBBB in their ECG and a QRS width of more than 130 msec, preferably > 150 msec.
CRTP/CRTD is like a pacemaker wherein three leads implanted into the heart through veins are connected to a generator, which is planted under the skin on the left side of the chest. This device improves pumping of the heart, symptoms, and survival and prevents cardiac sudden death.
CRT is a relatively old therapy, but new innovations in this device to improve its efficacy and responder rate is a continuous process.
Recently, medtronic company launched the most sophisticated device in the world named named Cobalt CRTD.

Cobalt CRTD cab be a Game-Changer in heart failure patients because of:

– Extended Battery Life: With a remarkable battery life of at least 10.1 years, Cobalt CRTD ensures long-term reliability.

– Enhanced Energy Delivery: Delivers 40J of energy per shock with a stored energy of 47J, providing robust support when needed.

– Seamless Connectivity: The BlueSync technology connects patients directly to their doctors, enabling real-time monitoring and early detection of heart failure decompensation up to 30 days before potential hospitalization.

– Advanced Algorithms: Cobalt CRTD offers the highest accuracy in AF detection and personalized ATP therapy, significantly reducing AF from 15% to almost negligible levels in this patient.

– Adaptive Pacing: The AdaptivCRT algorithm dynamically adjusts CRT parameters every minute based on patient’s activity and conduction status, ensuring optimal cardiac resynchronization.

– Effective CRT: The EffectivCRT feature maintains CRT benefits even during AF by adjusting the pacing rate.

– SmartShock Technology: With six advanced algorithms, SmartShock Technology reduces inappropriate shocks by 98.5%, enhancing patient safety.

Engineering the Extraordinary Cobalt CRTD represents a leap forward in patient care, offering unparalleled safety and benefits.